Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development
June 30th, 2025 6:00 PM
By: Newsworthy Staff
Lantern Pharma Inc. utilizes its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, marking a significant advancement in oncology drug discovery.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company, is making strides in oncology drug development through its innovative use of artificial intelligence (AI) and machine learning. The company's proprietary RADR(R) platform, which integrates over 200 billion oncology-specific data points, is at the forefront of this transformation. This technology supports the development of a pipeline of precision cancer therapies, including treatments for non-small cell lung cancer, triple-negative breast cancer, and non-Hodgkin’s lymphoma. Additionally, Lantern's Starlight Therapeutics initiative extends its research into brain and central nervous system cancers, including pediatric cases, supported by orphan and rare disease designations from the FDA. These efforts are underscored by the company's receipt of multiple FDA designations, such as Fast Track, Orphan Drug, and Rare Pediatric Disease status, which facilitate faster regulatory pathways for its therapies.
The significance of Lantern Pharma's work lies in its potential to drastically reduce the time and cost associated with bringing new cancer treatments to market. By leveraging AI, Lantern has been able to advance drug programs from initial insights to clinical trials in just 2-3 years, at a fraction of the traditional cost. This approach not only accelerates the availability of new therapies for patients in need but also exemplifies the transformative power of AI in healthcare and drug development. For more information on Lantern Pharma's groundbreaking work, visit https://ibn.fm/s1B45.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
